Drug Trial Radar · NCT04998396
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
26
Planned (sponsor's estimate)
Start
Sep 8, 2021
Primary completion
Oct 13, 2026
Study completion Oct 8, 2032
Sponsor
- Lead sponsor
- Aspa TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 30 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
Conditions
- Canavan Disease
Interventions
AAV9 BBP-812Biological
Sterile solution for injection for 1-time use via volumetric infusion pump
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Baseline up to Week 52
- Change from Baseline to 12 Months Post-Infusion in Urine N-acetylaspartate (NAA) LevelsTime frame: Baseline, Month 12
- Change from Baseline to 12 Months Post-Infusion in Central Nervous System (CNS) NAA, as Measured by Magnetic Resonance Spectroscopy (MRS)Time frame: Baseline, Month 12
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital Oakland
Oakland, California · Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois · Recruiting
Massachusetts General Hospital (MGH); Center for Rare Neurological Diseases (CRND)
Boston, Massachusetts · Recruiting
Weill Cornell Medicine; Division of Pediatric Neurology
New York, New York · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.